Sometimes both kidneys are involved. The cancer spreads easily, most often to the lungs and other organs. About one-third of patients have spreading (metastasis) at the time of diagnosis.
Signs and tests:
Palpation of the abdomen may show a mass or organ enlargement, particularly of the kidney or liver. Men may have a varicocele in the testicles. (A varicocele that is only on the ride side is especially suspicious.)
Surgical removal of all or part of the kidney (nephrectomy ) is recommended. This may include removing the bladder or surrounding tissues or lymph nodes.
Radiation therapy does not usually work for renal cell carcinoma and, therefore, is not often used. Hormone treatments may reduce the growth of the tumor in some cases.
Chemotherapy is generally not effective for treating renal cell carcinoma. The drug interleukin-2 is effective, but toxic to patients. Other chemotherapy drugs have been used, but survival rates are short.
Current therapies include sorafenib (Nexavar), sunitinib (Sutent), and temsirolimus (Torisel). The biologic drug bevacizumab (Avastin) has also been used.
A cure is unlikely unless all of the cancer is removed with surgery.
The outcome depends on the degree of cancer spread. The survival rate is highest if the tumor is in the early stages and has not spread outside the kidney. If it has spread to the lymph nodes or to other organs, the survival rate is much lower.
Call your health care provider any time you see blood in the urine. Also call if you have any other symptoms of this disorder.
Prevention:
Stop smoking. Follow your health care provider's recommendations in the treatment of kidney disorders, especially those that may require dialysis.
References:
US Food and Drug Administration. FDA Approves New Treatment for Advanced Kidney Cancer. Rockville, MD: National Press Office; December 20, 2005. Press Release P05-107.
Review Date: 6/10/2008 Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.